Primary navigation

    Inlyta

    Drug - Inlyta

    June 2012

    Therapeutic area - Oral Oncology

    Approval criteria

    • Patient has diagnosis of renal cell carcinoma AND
    • Patient has tried and failed 1 of the following drugs: sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab, or pazopanib

    Quantity limit

    Quantity Limit = 136 tablets

    Background information

    INLYTA is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. The 2012 NCCN guidelines for patient with clear cell histology recommend axitinib in patients who have failed at least one prior systemic therapy, oral or injectable.

    Inlyta is subject to quantity level limits and prior authorization.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top